Mumbai, India and Munich, Germany: December 29, 2022 – Cipla Limited (BSE: 500087;
NSE: CIPLA EQ) referred to as “Cipla” today announced that its wholly-owned UK
subsidiary, Cipla (EU) Limited (“Cipla EU”) has signed definitive agreements for equity
investment of EUR 15 million in Ethris GmbH (“Ethris”), a global leader in delivering
mRNAs directly to the respiratory system including administration by inhalation.

The investment will facilitate a long-term strategic partnership between Cipla and
Ethris for the development of messenger RNA (mRNA)-based therapies and fast-track
Cipla’s participation in the mRNA space, enabling it to provide access to cuttingedge
solutions developed by Ethris for the developing countries.

A collaboration agreement is signed concurrently with the definitive agreement,
which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging
markets.

The transaction is expected to get completed within 60 days from the date of signing
of the agreement or such other time-period as may be mutually agreed between the
parties in writing and shall be subject to completion of necessary regulatory
formalities.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said: “This
collaboration accelerates our innovation journey and enables us to provide access
to cutting-edge healthcare solutions to our patients. We expect mRNA-based
therapies to be one of the key innovation levers for Cipla. This inhaled mRNA
technology is a paradigm shift in the delivery mechanism and this partnership
reinforces Cipla’s strength in respiratory therapy in line with our aspiration of attaining
global lung leadership.”

Dr. Carsten Rudolph, CEO of Ethris stated: “We value this strategic relationship with
Cipla that will build on our pioneering mRNA technology and our joint focus on
bringing innovative treatments for respiratory diseases to patients. The investment
supports the further development of our pipeline and our objective to leverage the
power of mRNA-based therapeutics to treat a broad range of diseases.”

About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and
sustainable growth, complex generics, and deepening portfolio in our home markets
of India, South Africa, North America, and key regulated and emerging markets. Our
strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS
segments are well-known. Our 47 manufacturing sites around the world produce 50+
dosage forms and 1,500+ products using cutting-edge technology platforms to cater
to our 86 markets. Cipla is the 3rd largest in pharma in India (IQVIA MAT November ‘22),
3rd largest in the pharma private market in South Africa (IQVIA MAT October ‘22) and
is among the most dispensed generic players in the U.S. For over eight decades,
making a difference to patients has inspired every aspect of Cipla’s work. Our
paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a
dollar a day in Africa in 2001 is widely acknowledged as having contributed to
bringing inclusiveness, accessibility and affordability to the centre of the HIV
movement. A responsible corporate citizen, Cipla’s humanitarian approach to
healthcare in pursuit of its purpose of “Caring for Life” and deep-rooted community
links wherever it is present make it a partner of choice to global health bodies, peers
and all stakeholders.
For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

Media Contacts:
Corporate Communications                                             
Heena Kanal                                                                        
E-Mail: [email protected]                                      

Investor Relations 

Naveen Bansal 

E-Mail: [email protected] 

About Ethris
Ethris has paved a new path from genes to therapeutic proteins, using its proprietary
messenger RNA technology platform to discover, design and develop innovative
therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in
delivering stabilised mRNAs directly to the respiratory system via optimised formulation
and nebulisation technologies. The company is rapidly advancing its mRNA pipeline
of immuno-modulation, protein replacement therapies, and differentiated vaccines
against viral infections, with the ultimate goal of improving patients’ lives.
For more information, visit www.ethris.com

For Ethris, please contact:
Dr. Carsten Rudolph
+49 89 8955788 10
[email protected]

Media Relations
Gretchen Schweitzer 
Trophic Communications 

+49 172 861 8540 

[email protected]